How important is hanging onto your job during a recession?

There’s a new paper in an open-access journal called eCancer Medical Science that is asking a really tough question about links between unemployment and risk for prostate cancer mortality in the European Union nations. … READ MORE …

Optimal brachytherapy pre-treatment for intermediate-risk patients depends on “favorable” or “unfavorable” status

Anthony D’Amico has been advocating breaking up the intermediate-risk category into “favorable” and “unfavorable,” and now offers yet another circumstance where the optimal treatment is different for each of the two groups, this time with brachytherapy. … READ MORE …

Predicting risk for cancer years before the event

There is a lot of media hype about a paper just published in the online journal EBioScience. The paper suggests that it may, perhaps, be able to project risk for diagnosis of cancer (prostate cancer specifically included) as much as 13 years before the actual event. … READ MORE …

Over-use of some supplements can increase risk for cancer

Data presented at the annual meeting of the American Association for Cancer Research here in Philadelphia have again confirmed that the use of selenium and vitamin E supplements to raise levels of these agents to higher than normal levels is not a very good idea when it comes to cancer prevention. … READ MORE …

Race, obesity, and risk for prostate cancer

By using data from the prospective SELECT trial (the Selenium and Vitamin E Cancer Prevention Trial, conducted between 2001 and 2011), researchers have been able to suggest that obesity is strongly associated with increased risk for prostate cancer diagnosis among African American males compared to non-Hispanic whites. … READ MORE …

Are prostate cancer-specific mortality rates in Australia higher than they should be?

An article just published in the World Journal of Urology has suggested that rates of prostate cancer-specific mortality in Australia seem to have been unexpectedly higher than in the USA. … READ MORE …

New data on 5-ARI treatment in prevention of and and risk for prostate cancer

A new article in the journal JAMA Oncology has again suggested that the use of 5α-reductase inhibitors (5-ARIs) like finasteride/Proscar and dutasteride/Avodart is not, in fact, associated with any significant risk for clinically significant prostate cancer let alone risk for prostate cancer-specific mortality. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,285 other followers